Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Lotronex
Alosetron is a selective 5-HT3 receptor antagonist indicated for the treatment of severe diarrhea-predominant irritable bowel syndrome (IBS-D) in women who have not responded adequately to conventional therapy. It belongs to the class of serotonin receptor antagonists and works by blocking the action of serotonin at 5-HT3 receptors in the gut, which reduces gastrointestinal motility and visceral sensation, thus relieving symptoms of IBS-D.
For the treatment of severe diarrhea-predominant irritable bowel syndrome (IBS-D) in women who have not responded to conventional therapy.
ALOSETRON HYDROCHLORIDE CAN CAUSE SERIOUS COMPLICATIONS OF ISCHEMIC COLITIS AND COMPLICATED CONSTIPATION, INCLUDING DEATH. PRESCRIBE ALOSETRON ONLY FOR WOMEN WITH SEVERE DIARRHEA-PREDOMINANT IBS WHO HAVE NOT RESPONDED TO CONVENTIONAL THERAPY. PATIENTS MUST BE ABLE AND WILLING TO COMPLY WITH ALL REQUIRED ELEMENTS OF THE LOTRONEX REMS PROGRAM.
Outcome:
Increased alosetron levels, leading to increased risk of adverse effects.
Mechanism:
Fluvoxamine inhibits CYP1A2, the enzyme responsible for alosetron metabolism.
Outcome:
Additive anticholinergic effects.
Mechanism:
Both drugs have anticholinergic properties.
Outcome:
No clinically significant interaction expected.
Mechanism:
Different mechanisms of action.
Most likely new formulation: Extended-release alosetron (Year 2026, 30% confidence)
Based on current usage trends and safety profile, there is a low (<5%) likelihood of alosetron being withdrawn from the market in the next 5 years.
Serotonin 5-HT3 Receptor Antagonist
Indole derivative